New combo aims to boost existing cancer Drug's power
NCT ID NCT06659341
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new experimental drug, BAY 3498264, combined with the approved cancer drug sotorasib in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to find a safe dose and see if the combination can make sotorasib work longer or better. About 104 participants will receive the drugs in cycles, and researchers will monitor side effects, drug levels, and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BAY 3498264 (a SOS1 inhibitor) combined with sotorasib
What this could lead to
If successful, this combination could extend the time that sotorasib works in people with KRAS G12C cancers, potentially leading to longer disease control.
What could go wrong
This is a very early Phase 1 trial with only 104 participants. The main goal is safety and dosing, not proof of effectiveness. The combination may cause unexpected side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS HARBORING KRAS G12C MUTATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Border Medical oncology - Albury Wodonga Regional Cancer Centre
RECRUITINGAlbury, New South Wales, 2640, Australia
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica
RECRUITINGRome, Lazio, 00168, Italy
-
Hospital Universitari Vall D Hebron | Oncologia
NOT_YET_RECRUITINGBarcelona, 08035, Spain
-
Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia
RECRUITINGRozzano, 20089, Italy
-
Institut Catala D'oncologia | Hospitalet | Oncologia
RECRUITINGL'Hospitalet de Llobregat, Barcelona, 8907, Spain
-
Macquarie University Hospital - Oncology Department
RECRUITINGMacquarie Park, New South Wales, 2109, Australia
-
Peninsula and Southeast Oncology
RECRUITINGFrankston, Victoria, 3199, Australia
-
Rigshospitalet Copenhagen University Hospital | Oncology Department
RECRUITINGCopenhagen, Capital Region, 2100, Denmark
-
The Christie NHS Foundation Trust - Christie Hospital
RECRUITINGManchester, Greater Manchester, M20 4BX, United Kingdom
-
The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton
RECRUITINGSutton, Surrey, SM2 5PT, United Kingdom